BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18925847)

  • 1. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.
    Escudier B; Cosaert J; Pisa P
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1545-57. PubMed ID: 18925847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
    McDermott DF; George DJ
    Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
    Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
    BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
    Rini BI; Halabi S; Taylor J; Small EJ; Schilsky RL;
    Clin Cancer Res; 2004 Apr; 10(8):2584-6. PubMed ID: 15102658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
    Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
    Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for patients with metastatic renal cancer: an update.
    Yang JC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6367S-70S. PubMed ID: 15448032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
    Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
    J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.
    Melichar B; Procházková-Študentová H; Vitásková D
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1253-61. PubMed ID: 23136836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 16. Advanced renal cell carcinoma: current and emerging management strategies.
    Escudier B
    Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
    Rini BI; Small EJ
    J Clin Oncol; 2005 Feb; 23(5):1028-43. PubMed ID: 15534359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
    Yang JC; Haworth L; Sherry RM; Hwu P; Schwartzentruber DJ; Topalian SL; Steinberg SM; Chen HX; Rosenberg SA
    N Engl J Med; 2003 Jul; 349(5):427-34. PubMed ID: 12890841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.